QuVa Pharma
QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures compounded, ready-to-administer sterile injectable medications for over 3,000 U.S. hospitals, complemented by its BrightStream AI-powered pharmacy analytics platform acquired in 2024.
- Company typePrivate
- Founded2015
- HeadquartersSugar Land, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What QuVa Pharma does
QuVa Pharma is a privately held, FDA-registered 503B outsourcing facility founded in 2015 and headquartered in Sugar Land, Texas. The company manufactures compounded and ready-to-administer sterile injectable medications for hospital pharmacies across all 50 U.S. states, serving over 3,000 hospitals through direct enterprise sales and national group purchasing agreements — most notably with Premier, Inc. Its core portfolio includes low-dose fentanyl syringes, enhanced tamper-evident CADD cassettes, del Nido cardioplegia solution, and a broader ready-to-administer injectable line supported by forward distribution centers and remote direct distribution capabilities.
The company's go-to-market combines direct enterprise field sales to hospital pharmacy leadership with GPO channel partnerships that provide pre-negotiated pricing for member hospitals. In July 2024, QuVa acquired LogicStream Health and rebranded it as Quva BrightStream, adding an AI-powered clinical data and analytics platform comprising six modules — Shortage Navigator, Diversion Surveillance, Supply Advisor, Script Revenue Capture, Contracts Value Maximizer, and Clinical Process Optimizer — that process data from over 350 health-system data sets to deliver predictive shortage management, controlled-substance monitoring, inventory optimization, and revenue retention analytics.
QuVa is backed by Bain Capital (including its January 2024 $15 million equity investment) and previously financed through a $275 million senior debt facility led by Goldman Sachs and Owl Rock in 2021. The business model is dual-track: product revenue from sterile injectable compounding sold through enterprise and GPO channels, plus an emerging SaaS analytics revenue stream through BrightStream that is now embedded into the same Premier GPO procurement vehicle.
QuVa Pharma firmographics
Firmographics- Name
- QuVa Pharma
- Legal name
- QuVa Pharma, Inc.
- Website
- https://quvapharma.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures compounded, ready-to-administer sterile injectable medications for over 3,000 U.S. hospitals, complemented by its BrightStream AI-powered pharmacy analytics platform acquired in 2024.
- Ownership category
- akta.pro rank
QuVa Pharma industry classification
Industry- Product category
- 503B Sterile Injectable Compounding
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)
- akta.pro secondary industries
- Medication Inventory, Procurement & Supply Chain (Pharmacy) (HLACAKAI), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)
Keywords
Where QuVa Pharma is headquartered
LocationHeadquarters
- HQ city
- Sugar Land
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
QuVa Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- 503B Sterile Compounding Services: FDA-registered 503B outsourcing services providing compounded sterile injectable medications to hospitals. Revenue generated through product sales and service agreements with health systems.
- AI & Data Analytics Solutions (BrightStream): SaaS-based analytics and software solutions for health-system pharmacy performance improvement, including drug diversion surveillance, shortage management, and revenue optimization.
- Ready-to-Administer Portfolio: Pre-packaged, ready-to-administer sterile injectable medications that reduce medication errors and improve pharmacy efficiency.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
QuVa Pharma product offering
Product offeringCore offering
QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures and distributes compounded, ready-to-administer sterile injectable medications to over 3,000 U.S. hospitals across all 50 states. Through its Quva BrightStream platform (acquired LogicStream Health in July 2024), the company also delivers AI-powered analytics solutions, including drug diversion surveillance, shortage management, supply optimization, and revenue capture for health-system pharmacies. The combined offering pairs physical pharmaceutical manufacturing with data-driven pharmacy intelligence.
Product overview
QuVa Pharma operates as a dual-platform company offering pharmaceutical manufacturing and AI-powered analytics solutions. The core QuVa Pharma platform provides FDA-registered 503B sterile injectable compounding services, delivering ready-to-administer medications to over 3,000 U.S. hospitals across all 50 states. Complementing this is the Quva BrightStream platform (acquired LogicStream Health in July 2024), which offers six AI-powered analytics modules including Shortage Navigator, Diversion Surveillance, Supply Advisor, Script Revenue Capture, Contracts Value Maximizer, and Clinical Process Optimizer. Together, these platforms enable health-system pharmacies to access both essential sterile medications and data-driven insights from over 350 data sets to improve operational performance and patient outcomes.
Differentiator
Problem solved
Functional benefit
Brands
- Quva BrightStream: AI-powered analytics and data insights platform for health-system pharmacy, offering solutions including shortage navigator, diversion surveillance, supply advisor, script revenue capture, contracts value maximizer, and clinical process optimizer. Formerly known as LogicStream Health.
- Quva Pharma Ordering Portal
- BrightStream SaaS Portal
Products and services
- 503B Sterile Compounding Services FDA-registered 503B outsourcing services providing essential, compounded, ready-to-administer sterile injectable medicines to over 3,000 U.S. hospitals across all 50 states, with industry-first remote direct distribution capabilities and state-of-the-art production facilities.
- Ready-to-Administer Portfolio Pre-made sterile injectable medications ready for direct patient administration, designed to reduce medication errors and improve pharmacy efficiency in hospital settings.
- New 503B Product Development Custom sterile injectable product development services for new 503B compounded medications to address unmet hospital needs.
- del Nido Cardioplegia Solution Sterile cardioplegia solution designed for cardiac surgery, manufactured and distributed as a ready-to-administer compounded sterile injectable.
- FentaNYL (Low Dose Fentanyl Syringe) Preservative-free sterile injectable fentanyl syringe featuring room temperature storage and a 90-day Beyond Use Date (BUD).
- CADD Cassettes Sterile injectable cassettes with enhanced tamper-evident cap and packaging to support prevention of leakage and diversion in hospital pharmacy settings.
- Quva BrightStream Analytics Platform AI-powered analytics and data insights platform (formerly LogicStream Health) that transforms fragmented health-system data from over 350 data sets into actionable intelligence to improve pharmacy performance and patient outcomes, including drug diversion surveillance, shortage management, and supply optimization.
Quantifiable outcome
- Serves over 3,000 U.S. hospitals
- +1 more outcomes
Companies that use QuVa Pharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
QuVa Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
QuVa Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Premier, Inc.coreQuVa Pharma secured a national group purchasing agreement with Premier, Inc. for its Drug Diversion Software Solutions, effective May 1, 2026. This agreement enhances Premier members' access to QuVa's BrightStream solutions, which help safeguard controlled substances and improve pharmacy compliance and oversight.
- Premier, Inc.coreQuVa Pharma was awarded a national group purchasing agreement for outsourced compounded preparations with Premier, Inc., effective November 1, 2025. This agreement allows Premier members to benefit from pre-negotiated pricing and supports QuVa's role as a provider of sterile injectable compounding services.
- LogicStream HealthcoreQuVa Pharma completed the acquisition of LogicStream Health in July 2024, creating an integrated healthcare platform combining pharmaceutical distribution and AI-powered clinical data solutions. LogicStream Health has been rebranded as BrightStream and provides predictive analytics, drug diversion surveillance, and other pharmacy optimization solutions.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
QuVa Pharma competitors and assessment
Company assessmentDirect peers
- Central Admixture Pharmacy Services (CAPS): Owned by B. Braun, CAPS is one of the largest 503B sterile compounding outsourcing networks in the U.S., directly competing with QuVa across the same hospital pharmacy customer base and FDA-registered outsourcing facility model.
- Pharmedium Services: Pharmedium, owned by Cencora (formerly AmerisourceBergen), is a leading 503B sterile injectable compounder serving U.S. hospitals — the closest direct competitor to QuVa with the added distribution scale of a Big-3 pharmaceutical wholesaler parent.
- WG Critical Care: WG Critical Care is a specialty 503B sterile compounder supplying hospitals with ready-to-administer injectable preparations, competing with QuVa in similar product categories and hospital pharmacy channels.
- Cantrell Drug Company: Cantrell Drug Company is an FDA-registered 503B outsourcing facility providing sterile compounded preparations to hospitals and health systems, overlapping directly with QuVa's compounding portfolio and customer segment.
- Olympia Pharmaceuticals: Olympia Pharmaceuticals operates as a 503B outsourcing compounder serving hospital and clinical customers with sterile injectable preparations, directly competing with QuVa in the outsourced sterile injectable category.
- Pentec Health: Pentec Health is a specialty sterile compounding provider serving patients and provider organizations with parenteral nutrition and intrathecal therapies, overlapping with QuVa in sterile outsourced preparations for clinical settings.
Broad incumbents
- Cencora (formerly AmerisourceBergen): Cencora is one of the Big-3 U.S. pharmaceutical distributors and owns Pharmedium, the closest direct 503B peer of QuVa. As a parent of a direct competitor, Cencora is a broad incumbent whose scale, wholesaler relationships, and capital base exceed QuVa's.
- B. Braun Medical: B. Braun owns CAPS (Central Admixture Pharmacy Services), a direct 503B competitor to QuVa, and is itself a major manufacturer of IV solutions and sterile injectables. B. Braun is a broad incumbent operating across QuVa's category with deeper balance-sheet resources.
- McKesson: McKesson is one of the largest U.S. pharmaceutical distributors and a major player in hospital drug supply, broad-line injectable distribution, and pharmacy services — overlapping with QuVa's hospital-customer base from a wholesaler and services angle.
Emerging players
- Omnicell: Omnicell is a leading pharmacy automation and analytics vendor for health systems; its medication-use analytics and diversion-surveillance capabilities overlap meaningfully with QuVa BrightStream's modules, making it a partial-overlap emerging competitor in the pharmacy-software layer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
QuVa Pharma social profiles
Digital presenceQuVa Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
QuVa Pharma leadership team
Management profileNumber of profiles
Profiles4 records
QuVa Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
QuVa Pharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QuVa Pharma M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QuVa Pharma
What does QuVa Pharma do?
QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures and distributes compounded, ready-to-administer sterile injectable medications to over 3,000 U.S. hospitals across all 50 states. Through its Quva BrightStream platform (acquired LogicStream Health in July 2024), the company also delivers AI-powered analytics solutions, including drug diversion surveillance, shortage management, supply optimization, and revenue capture for health-system pharmacies. The combined offering pairs physical pharmaceutical manufacturing with data-driven pharmacy intelligence.
Is QuVa Pharma a public or private company?
QuVa Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was QuVa Pharma founded?
QuVa Pharma was founded in 2015. It employs 1,001 to 5,000 people.
Where is QuVa Pharma based?
QuVa Pharma is headquartered in Sugar Land, United States, in the North America region.
How does QuVa Pharma make money?
Three revenue lines are on record. 503B Sterile Compounding Services are the primary driver. The others are AI & Data Analytics Solutions (BrightStream) and ready-to-Administer Portfolio.
Who are QuVa Pharma's main competitors?
Direct peers on record are Central Admixture Pharmacy Services (CAPS), Pharmedium Services, WG Critical Care, Cantrell Drug Company, Olympia Pharmaceuticals and Pentec Health. Broad incumbents are Cencora (formerly AmerisourceBergen), B. Braun Medical and McKesson. Omnicell is listed as an emerging player.
Does QuVa Pharma have an API?
No public API is recorded for QuVa Pharma.
What industry is QuVa Pharma in?
QuVa Pharma's product category is 503B Sterile Injectable Compounding. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLACAKAI, Medication Inventory, Procurement & Supply Chain (Pharmacy). Its NAICS code is 325412 and its SIC code is 2834.